Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,580 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Phase 2 Interventional

Probiotics in Newly Diagnosed T1D

NCT04141761
Conditions
Type 1 Diabetes, Type1diabetes, Type 1 Diabetes Mellitus
Interventions
Visbiome, Placebo
Dietary Supplement · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

NCT00938405
Conditions
Diabetes Mellitus, Type 1, Hyperlipidemias
Interventions
Colesevelam HCl, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
Interventions
R-5280, Placebo
Drug · Other
Lead sponsor
Rise Therapeutics LLC
Industry
Eligibility
11 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Plantation, Florida • Rochester, Minnesota • Dallas, Texas
Conditions
Type 1 Diabetes
Interventions
Lantus and short acting analogs Vs NPH and short acting analogs
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Results available

G-Pen™ for Hypoglycemia Rescue in T1D Patients

NCT02423980
Conditions
Hypoglycemia
Interventions
Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Walnut Creek, California
Conditions
Diabetic Gastroparesis
Interventions
10 mg TZP-102, Placebo
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Huntsville, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 19 more
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Type 1 Diabetes Mellitus
Interventions
Behavioral Family Systems Therapy for Diabetes
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 16 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Jacksonville, Florida • St Louis, Missouri
Conditions
Type 1 Diabetes
Interventions
Continuous glucose glucose sensor- physician ordered
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Type 1 Diabetes
Interventions
Anti-thymocyte globulin (ATG), verapamil extended release capsule, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Aurora, Colorado • Gainesville, Florida
Conditions
Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I
Interventions
Medtronic 780G AID
Device
Lead sponsor
Viral N. Shah
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Type 1 Diabetes (T1D)
Interventions
Automated Insulin Delivery (AID), AIDANET + Fully Closed Loop (FCL), AIDANET + Anticipatory Closed Loop (ACL)
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
No treatment given, survey
Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
BD/33G, OTM / 33G, OTU/28G, ACC/28G, OTM/28G
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Colorado Springs, Colorado • Carlstadt, New Jersey • Paramus, New Jersey + 1 more
Conditions
Diabetes Mellitus, Type I
Interventions
Real-time glucose sensor
Device
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
3 Months to 3 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Diabetes Complications, Diabetic Nephropathies, Autoimmune Diabetes
Interventions
Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF), Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Terminated No phase listed Observational Accepts healthy volunteers

Biological Sample Collection for Research and Biobanking

NCT04270604
Conditions
Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease
Interventions
Biological sample collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
1 Month to 100 Years
Enrollment
1,279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes Mellitus, Type 1
Interventions
IMCY-0098 450 μg, IMCY-0098 1350 μg, Placebo
Drug
Lead sponsor
Imcyse SA
Industry
Eligibility
18 Years to 44 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 1 more
Conditions
Pregnancy, High Risk, Type 1 Diabetes
Interventions
Insulin, DEXCOM Continuous Glucose Monitor
Drug · Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Type 1 Diabetes
Interventions
Transition Social Behavioral Intervention, Diabetes Transition Clinic
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
16 Years to 29 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
Interventions
GRT-C903, GRT-R904, nivolumab, ipilimumab
Biological
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
Conditions
Type 1 Diabetes
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
NovoFine® needle 6 mm, Ultra-Fine needle 12.7 mm
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Walnut Creek, California • Berlin, New Jersey • Lawrenceville, New Jersey + 2 more
Conditions
Type 1 Diabetes
Interventions
Family Teamwork-Peer Delivery
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Years to 10 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas